381 related articles for article (PubMed ID: 24512308)
41. The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma.
Newbold A; Salmon JM; Martin BP; Stanley K; Johnstone RW
Oncogene; 2014 Nov; 33(47):5415-23. PubMed ID: 24292681
[TBL] [Abstract][Full Text] [Related]
42. TRPM2 mediates histone deacetylase inhibition-induced apoptosis in bladder cancer cells.
Cao QF; Qian SB; Wang N; Zhang L; Wang WM; Shen HB
Cancer Biother Radiopharm; 2015 Mar; 30(2):87-93. PubMed ID: 25760728
[TBL] [Abstract][Full Text] [Related]
43. Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells.
Cortiguera MG; García-Gaipo L; Wagner SD; León J; Batlle-López A; Delgado MD
Sci Rep; 2019 Nov; 9(1):16495. PubMed ID: 31712669
[TBL] [Abstract][Full Text] [Related]
44. Prospects: histone deacetylase inhibitors.
Dokmanovic M; Marks PA
J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
[TBL] [Abstract][Full Text] [Related]
45. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
Jazirehi AR
Anticancer Drugs; 2010 Oct; 21(9):805-13. PubMed ID: 20679890
[TBL] [Abstract][Full Text] [Related]
46. Targeting Histone Deacetylases in Diseases: Where Are We?
Benedetti R; Conte M; Altucci L
Antioxid Redox Signal; 2015 Jul; 23(1):99-126. PubMed ID: 24382114
[TBL] [Abstract][Full Text] [Related]
47. Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53.
Mrakovcic M; Bohner L; Hanisch M; Fröhlich LF
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544838
[TBL] [Abstract][Full Text] [Related]
48. Epigenetic therapy of lymphoma using histone deacetylase inhibitors.
Cotto M; Cabanillas F; Tirado M; García MV; Pacheco E
Clin Transl Oncol; 2010 Jun; 12(6):401-9. PubMed ID: 20534395
[TBL] [Abstract][Full Text] [Related]
49. Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents.
Garcia-Manero G; Issa JP
Cancer Invest; 2005; 23(7):635-42. PubMed ID: 16305991
[TBL] [Abstract][Full Text] [Related]
50. P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivo molecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor.
Hsieh YJ; Hwu L; Chen YC; Ke CC; Chen FD; Wang HE; Lin KP; Yeh HH; Chang CW; Liu RS
J Nucl Med; 2014 Apr; 55(4):678-85. PubMed ID: 24639460
[TBL] [Abstract][Full Text] [Related]
51. Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation.
Yamaguchi H; Chen CT; Chou CK; Pal A; Bornmann W; Hortobagyi GN; Hung MC
Oncogene; 2010 Oct; 29(41):5619-29. PubMed ID: 20676141
[TBL] [Abstract][Full Text] [Related]
52. Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.
Raynal NJ; Da Costa EM; Lee JT; Gharibyan V; Ahmed S; Zhang H; Sato T; Malouf GG; Issa JJ
Mol Cancer Ther; 2017 Feb; 16(2):397-407. PubMed ID: 27980103
[TBL] [Abstract][Full Text] [Related]
53. Cancer cells' epigenetic composition and predisposition to histone deacetylase inhibitor sensitization.
Nalabothula N; Carrier F
Epigenomics; 2011 Apr; 3(2):145-55. PubMed ID: 21743813
[TBL] [Abstract][Full Text] [Related]
54. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.
Peart MJ; Smyth GK; van Laar RK; Bowtell DD; Richon VM; Marks PA; Holloway AJ; Johnstone RW
Proc Natl Acad Sci U S A; 2005 Mar; 102(10):3697-702. PubMed ID: 15738394
[TBL] [Abstract][Full Text] [Related]
55. Butyrate mediates decrease of histone acetylation centered on transcription start sites and down-regulation of associated genes.
Rada-Iglesias A; Enroth S; Ameur A; Koch CM; Clelland GK; Respuela-Alonso P; Wilcox S; Dovey OM; Ellis PD; Langford CF; Dunham I; Komorowski J; Wadelius C
Genome Res; 2007 Jun; 17(6):708-19. PubMed ID: 17567991
[TBL] [Abstract][Full Text] [Related]
56. Low-Dose Histone Deacetylase Inhibitor Treatment Leads to Tumor Growth Arrest and Multi-Lineage Differentiation of Malignant Rhabdoid Tumors.
Muscat A; Popovski D; Jayasekara WS; Rossello FJ; Ferguson M; Marini KD; Alamgeer M; Algar EM; Downie P; Watkins DN; Cain JE; Ashley DM
Clin Cancer Res; 2016 Jul; 22(14):3560-70. PubMed ID: 26920892
[TBL] [Abstract][Full Text] [Related]
57. Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells.
Laurenzana A; Balliu M; Cellai C; Romanelli MN; Paoletti F
PLoS One; 2013; 8(3):e58267. PubMed ID: 23469273
[TBL] [Abstract][Full Text] [Related]
58. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
Palani CD; Beck JF; Sonnemann J
Invest New Drugs; 2012 Feb; 30(1):25-36. PubMed ID: 20680659
[TBL] [Abstract][Full Text] [Related]
59. Class I histone deacetylases regulate p53/NF-κB crosstalk in cancer cells.
Schäfer C; Göder A; Beyer M; Kiweler N; Mahendrarajah N; Rauch A; Nikolova T; Stojanovic N; Wieczorek M; Reich TR; Tomicic MT; Linnebacher M; Sonnemann J; Dietrich S; Sellmer A; Mahboobi S; Heinzel T; Schneider G; Krämer OH
Cell Signal; 2017 Jan; 29():218-225. PubMed ID: 27838375
[TBL] [Abstract][Full Text] [Related]
60. Nrf2-miR-129-3p-mTOR Axis Controls an miRNA Regulatory Network Involved in HDACi-Induced Autophagy.
Sun W; Yi Y; Xia G; Zhao Y; Yu Y; Li L; Hua C; He B; Yang B; Yu C; Ye C; Tu F; Chen C; Xu X; Zheng Z; Wang W; Shen X
Mol Ther; 2019 May; 27(5):1039-1050. PubMed ID: 30852137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
